Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）

This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of orelabrutinib combined with the R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) regimen as first-line treatment in CD5-positive diffuse large B-cell lymphoma (DLBCL) patients.

Trial Details

NCT ID

NCT06647940

Phase

PHASE2

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Orelabrutinib Oral Tablet
R-CHOP Protocol

Locations (sample)

Guangzhou, China, China|23.11667,113.25
Lanzhou, Gansu, China|36.05701,103.83987
Dongguan, Guangdong, China|23.01797,113.74866
Guangzhou, Guangdong, China|23.11667,113.25
Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Subjects fully understand and voluntarily participate in this study and sign informed consent.
Aged ≥18 years, both male and female.
Pathologically confirmed CD5-positive DLBCL
There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →